About: Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $43.10 (+4.66%)
COAG NASDAQ Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics Holdings, Inc. Common Stock share price
COAG price activity
Last Price
$43.100
Change (24hr)
1.92 USD (4.66%)
Volume
462.14K
Volume (4w avg)
-
Open
$41.90
Day Range
$41.15 - $44.36
Previous Close
$41.18
Last Trade
03 Nov, 9:00 pm GMT+0
Delayed
03 Nov, 9:00 pm GMT+0
COAG price performance
Delayed
03 Nov, 9:00 pm GMT+0
COAG details
COAG Market Signals